Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,616 matching trials from the live ClinicalTrials.gov search.
Conditions
Macular Edema, Epiretinal Membrane, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Low Vision, Age Related Macular Degeneration
Interventions
Visual Feedback
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
14 Years to 99 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions
Color fundus photography, Mydriatic Agent
Procedure · Drug
Lead sponsor
Eyenuk, Inc.
Industry
Eligibility
18 Years and older
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diabetes
Interventions
Vessel measurements
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
5 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
La Jolla, California • Stanford, California • Atlanta, Georgia + 3 more
Conditions
Stargardt Disease
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
6 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Baltimore, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Conditions
Age-Related Macular Degeneration
Interventions
Palomid 529
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 4 Interventional Accepts healthy volunteers

Investigation of Macular Pigment Augmentation on Dark Adaptation

NCT00478439
Conditions
Aging, Age-Related Macular Degeneration
Interventions
ZeaVision EyePromise Restore, Multivitamin
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of PER-001 in Participants With Diabetic Retinopathy

NCT06003751
Conditions
Diabetic Retinopathy
Interventions
PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham
Drug
Lead sponsor
Perfuse Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PAN-90806 Ophthalmic Suspension
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Golden, Colorado • Hagerstown, Maryland • Henderson, Nevada + 5 more
Completed No phase listed Observational Accepts healthy volunteers

Functionally Validated Structural Endpoints for Early AMD

NCT04112667
Conditions
Age-related Macular Degeneration, Aging
Interventions
Normal Macular Health, Early Macular Degeneration, Young Normals
Other
Lead sponsor
Cynthia Owsley
Other
Eligibility
20 Years and older
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Completed No phase listed Observational

Evaluation of OCT Measurements

NCT01806402
Conditions
Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Interventions
Not listed
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Daly City, California • Petaluma, California • Walnut Creek, California
Conditions
Autoimmune Disease
Interventions
Rituximab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers Results available

Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration

NCT01115231
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
2
States / cities
Charleston, South Carolina • Houston, Texas
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy Product-MCO-010, Sham Injection
Biological · Procedure
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Active, not recruiting No phase listed Observational

Impact of Non-Exudative Type 1 MNV on AMD Progression

NCT06125977
Conditions
Age-Related Macular Degeneration, Neovascularization, Choroidal
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
73 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Diabetic Retinopathy
Interventions
Aminoguanidine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Retinoblastoma
Interventions
Proton Beam Radiation Therapy, Ophthalmic EUA
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Epiretinal Membrane
Interventions
27-gauge vitrectomy wound construction
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

Sirolimus to Treat Diabetic Macular Edema

NCT00711490
Conditions
Diabetic Retinopathy
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Phase 2 Interventional

Bevacizumab Treatment For Type 1 ROP

NCT04634578
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 20 more
Completed Phase 2Phase 3 Interventional Results available

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

NCT02858076
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Interventions
2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
60
States / cities
Campbell, California • Glendale, California • Huntington Beach, California + 50 more
Conditions
Leber Congenital Amaurosis
Interventions
Not listed
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

An Extension to Study MD7108240

NCT00733304
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more